Article
Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration.
Neurology - 22 Oct 2024
Vandebergh Marijne, Ramos Eliana Marisa, Corriveau-Lecavalier Nick, Ramanan Vijay K, Kornak John, Mester Carly, Kolander Tyler, Brushaber Danielle E, Staffaroni Adam M, Geschwind Daniel H, Wolf Amy A, Kantarci Kejal, Gendron Tania, Petrucelli Leonard, Van den Broeck Marleen, Wynants Sarah, Baker Matthew, Borrego-Écija Sergi, Appleby Brian, Barmada Sami, Bozoki Andrea C, Clark David, Darby R Ryan, Dickerson Bradford C, Domoto-Reilly Kimiko, Fields Julie A, Galasko Douglas, Ghoshal Nupur, Graff-Radford Neill R, Grant Ian M, Honig Lawrence S, Hsiung Ging-Yuek R, Huey Edward D, Irwin David J, Knopman David S, Kwan Justin Y, Léger Gabriel C, Litvan Irene, Masdeu Joseph C, Mendez Mario F, Onyike Chiadi U, Pascual Belen, Pressman Peter S, Ritter Aaron, Roberson Erik D, Snyder Allison, Sullivan Anna Campbell, Tartaglia Maria Carmela, Wint Dylan, Heuer Hilary W, Forsberg Leah K, Boxer Adam L, Rosen Howard J, Boeve Bradley F, Rademakers Rosa
Abstract excerpt
BACKGROUND AND OBJECTIVES: TMEM106B has been proposed as a modifier of disease risk in FTLD-TDP, particularly in GRN pathogenic variant carriers. Furthermore, TMEM106B has been investigated as a disease modifier in the context of healthy aging and across multiple neurodegenerative diseases. The objective of this study was to evaluate and compare the effect of TMEM106B on gray matter volume and cognition in each...
Read the complete abstract on PubMed